Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Axsome Therapeutics Inc

Current price
67.9 USD +2.4 USD (+3.66%)
Last closed 65.72 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 3 275 939 840 USD
Yield for 12 month -4.76 %
21.11.2021 - 28.11.2021

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York. Address: One World Trade Center, New York, NY, United States, 10007

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
MSFT MSFT Microsoft


WallStreet Target Price

123 USD

P/E ratio

Dividend Yield

Current Year

+270 600 000 USD

Last Year

+50 037 106 USD

Current Quarter

+71 530 000 USD

Last Quarter

+57 794 000 USD

Current Year

+237 701 000 USD

Last Year

+44 839 511 USD

Current Quarter

+64 152 000 USD

Last Quarter

+51 262 000 USD

Key Figures AXSM

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -182 448 000 USD
Operating Margin TTM -77.68 %
PE Ratio
Return On Assets TTM -24.86 %
PEG Ratio
Return On Equity TTM -159.21 %
Wall Street Target Price 123 USD
Revenue TTM 270 600 000 USD
Book Value 4.03 USD
Revenue Per Share TTM 5.96 USD
Dividend Share
Quarterly Revenue Growth YOY 193.5 %
Dividend Yield
Gross Profit TTM 45 939 511 USD
Earnings Share -5.27 USD
Diluted Eps TTM -5.27 USD
Most Recent Quarter IV 2023
Quarterly Earnings Growth YOY
Profit Margin -88.41 %

Dividend Analytics AXSM

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History AXSM

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation AXSM

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 11.3678
Price Sales TTM 12.1062
Enterprise Value EBITDA -13.6722
Price Book MRQ 17.1536

Financials AXSM

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators AXSM

For 52 weeks

55.02 USD 98.4 USD
50 Day MA 80.43 USD
Shares Short Prior Month 7 297 793
200 Day MA 74.94 USD
Short Ratio 8.86
Shares Short 7 650 712
Short Percent 19.44 %

Dynamics of changes in the value of assets




399.12 USD Microsoft Corporation -4.91 (-1.22%)
Detailed analytics

ETF funds



207.85 CHF iShares MDAX UCITS ETF (DE) 0 (0%)
Detailed analytics



2175.88 USD Gold +5.94 (+0.27%)
Detailed analytics